N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Property

Boiling point:

589.9±50.0 °C(Predicted)

Density 

1.125±0.06 g/cm3(Predicted)

storage temp. 

Keep in dark place,Sealed in dry,2-8°C

solubility 

DMSO: soluble2mg/mL, clear (warmed)

pka

9.05±0.20(Predicted)

form 

A crystalline solid

color 

white to beige

InChI

InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2

InChIKey

IXEPQJQQSLMESJ-UHFFFAOYSA-N

SMILES

C(NCC1=CC=C(C2=NC=CC=C2)C=C1)CNCC1=CC=C(C2=NC=CC=C2)C=C1

Safety

Hazard Codes 

Xn

Risk Statements 

22

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Chemical Properties,Usage,Production

Description

BC-1215 (N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine) is an inhibitor of F-box protein 3 (FBXO3; IC50 = 0.9 μg/mL for Il-1β release). It decreases FBXO3 interaction with F-box/LRR-repeat protein 2 (FBXL2) in a dose-dependent manner and prevents FBXO3-dependent ubiquitination of FBXL2. It also lowers expression of Tnf receptor-associated factors (TRAFs) 1-6 without affecting TRAF1-6 mRNA levels in resting and LPS-stimulated peripheral blood mononuclear cells (PBMCs). BC-1215 (100 μg, i.p., per animal) reduces plasma levels of the inflammatory cytokines Il-6, Tnf, and Il-1β and decreases peritoneal bacteria counts in a mouse model of cecal ligation and puncture-induced sepsis. It also reduces inflammation in mouse models of DSS-induced colitis, paw edema, and ear edema.